Share this story:

Ventripoint Signs on Arc Group Medical LLC as Distributor in Florida Region



Ventripoint Diagnostics Ltd.
 

Toronto, Ontario – The Newswire – November 30, 2022 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that it has signed Arc Group Medical LLC as a distributor for the US - Florida reghion. 

Arc Group Medical (www.arcgmed.com) covers the entire Florida region and has over five years of direct cardiology sales experience and around fifteen years cumulatively. Within those five years, Arc Group Medical has been integrated within over fifty sites across Florida. This partnership will help diversify Ventripoint’s reach within the US market. The experience working exclusively in the cardiology sector will benefit Ventripoint because of the established relationships the distributor has. 

Arc Group Medical President and Regional Distributor, Antonio Cancel, states “We look forward to partnering with Ventripoint to introduce this ground-breaking technology to our healthcare partners throughout the state of Florida.”

Ventripoint looks forward to the partnership with Arc Group Medical and is confident that the VMS+ will grow its reach throughout Florida.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

 

Dr. George Adams

gadams@ventripoint.com

519-803-6937

 

 Neither the TSX Venture Exchange nor its Regulation Services Provider (as

 that term is defined in the policies of the TSX Venture Exchange) accepts

 responsibility for the adequacy or accuracy of this news release.

 

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward- looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward- looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.